New Pharmaceuticals research report from GlobalData is now available from Fast Market Research

Boston, MA -- (SBWire) -- 12/12/2013 --Hemophilia is an X-linked hereditary bleeding disorder characterized by impaired blood coagulation as a result of deficiencies in the production or function of coagulation factor VIII (hemophilia A) or factor IX (hemophilia B). Because of the deficiency of coagulation factor, hemophilia patients have a tendency for bleeding in joints, muscles, soft tissues and within mucous membranes, which can be spontaneous or could be due to internal or external trauma, depending on the severity of the disease. The clinical presentation of hemophilia ranges from mild to moderate to severe stages depending on the residual level of the circulating factor (Rocino et al., 2012; Srivastava et al., 2012; White et al., 2001).

Hemophilia is a rare disease but the prevalence of hemophilia varies according to the economic status of a country. The exact cause for the variation in prevalence between countries based on their economic status is unknown. However, researchers attribute the lower prevalence in lower-income countries to insufficient reporting of these data due to the lack of access to healthcare and impaired diagnostic capabilities because of little or no treatment due to lower economic funds in low-income countries (Evatt, 2005; Skinner, 2006; Stonebraker et al., 2010).

View Full Report Details and Table of Contents

In 2012, the 9MM had 56,762 diagnosed prevalent cases of hemophilia A and B, 30% of which occurred in the US. The diagnosed prevalent cases of hemophilia in the 9MM are expected to increase slightly to 58,072 cases by 2022 (Figure 1). Throughout the forecast for the 9MM, the US will have the largest proportion of diagnosed prevalent cases of hemophilia A and B, with 30.90% of all the diagnosed prevalent cases of hemophilia A and B in the 9MM. Because hemophilia is an inherited condition, it requires lifelong treatment. Given the increase in prevalence of cardiovascular diseases with advancing age and increasing life expectancy in hemophiliacs due to advances in treatment, the challenges faced by hemophiliacs may increase in the near future, as well as the need for supporting treatments and care.

Scope

- The Hemophilia EpiCast Report provides an overview of the risk factors and epidemiological trends for hemophilia in the nine major markets (9MM) (US, France, Germany, Italy, Spain, UK, Japan, Argentina, and China). It includes a 10-year epidemiological forecast of the diagnosed prevalent cases of both hemophilia A and B segmented by age, (ages 0 to greater or equal to 85 years), and sex in these markets.
- The Hemophilia epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 9MM.

Reasons to Get This Report

- Develop business strategies by understanding the trends shaping and driving the global hemophilia market.

About Fast Market Research
Fast Market Research is an online aggregator and distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff will help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

Browse all Pharmaceuticals research reports at Fast Market Research

You may also be interested in these related reports:

- EpiCast Report: Overweight and Obesity - Epidemiology Forecast to 2022
- EpiCast Report: Diabetic Foot Ulcers - Epidemiology Forecast to 2022
- EpiCast Report: Pediatric Respiratory Syncytial Virus Infection and Prophylactic Populations in the US - Epidemiology Forecast to 2022
- EpiCast Report: Trigeminal Neuralgia - Epidemiology Forecast to 2022
- EpiCast Report: Psoriasis - Epidemiology Forecast to 2022
- EpiCast Report: Gram-Negative Bacterial Pneumonia - Epidemiology Forecast to 2022
- EpiCast Report: Postmenopausal Vaginal Atrophy - Epidemiology Forecast to 2022
- EpiCast Report: Gram-Negative Bacterial Urinary Tract Infection - Epidemiology Forecast to 2022
- EpiCast Report: Dry Eye Syndrome - Epidemiology Forecast to 2022
- EpiCast Report: Systemic Lupus Erythematosus Epidemiology Forecast to 2022